Medicilon Inc.’s Post

In PK studies, special administration methods may increase drug concentration in the target tissue, enhance therapeutic effects, or reduce the incidence of adverse reactions. Yufeng Meng, the Assistant Director of #DMPK at Medicilon, provides insights on the techniques and applications of target organ biopsy in PK studies. This information aims to help reduce confusion and challenges in #PK trials.

🔬 New Research Alert! published in #DrugDevIndPharm 🌟 Nintedanib and miR-29b co-loaded lipoplexes in idiopathic pulmonary fibrosis: formulation, characterization, and in vitro evaluation 🌟 The study explores the development of a novel lipoplex formulation co-loaded with Nintedanib and miR-29b for treating idiopathic pulmonary fibrosis (IPF). Utilizing a quality by design (QbD) approach, the research optimized the formulation to achieve high encapsulation efficiency and stability, demonstrating controlled release and significant anti-fibrotic effects in vitro. The lipoplexes showed enhanced delivery and efficacy in reducing fibrotic markers in NIH/3T3 cells, suggesting potential for improved IPF therapy. This pioneering work marks the first co-delivery of Nintedanib and miR-29b in a liposomal system, offering a promising strategy for IPF treatment. 📖 Read the full article here: https://lnkd.in/ggsXvRfq #InnovativeTherapy #PulmonaryFibrosis #DrugDevelopment #Biotechnology #PharmaceuticalResearch

#MCBPoster24 #USTBiochem #Chronicrespiratoryfailure #marinobufagenin #medchem #USTrepresent An increased incidence of chronic respiratory failure has been observed in hospitalized patients, compelling the need to search for alternative therapeutics that are safer and more natural than traditional respiratory analeptics. We employ computer-aided drug discovery tools (CADD) such as molecular docking and molecular dynamics to exploit the abilities of marinobufagenin and its derivatives to interact with TWIK-associated acid-sensitive potassium channel 3 (TASK-3) and evaluate its pharmacokinetics and pharmacodynamics parameters. In this research poster presentation, we report that marinobufagenin, marinosin, and marinobufagenin-3-sulfate from R. marina (L.)  exhibited binding affinities comparable to standard respiratory analeptics. Both marinobufagenin (0.13) and marinobufagenin-3-sulfate (0.02) have shown high activity in ion channel modulation (ion channel modulator > 0.00, high activity. All compounds showed favorable pharmacokinetic properties. Molecular dynamics revealed that marinobufagenin-3-sulfate exhibited the most robust protein-ligand interaction with TASK-3 (KCNK9) as indicated by the average RMSD and RMSF values and plots, which are within an acceptable range and lower as compared to the free state of KCNK9.

#ACROHighlights [Featured Product] 🚀 Harnessing Cardiac Organoids for Enhanced Drug Development 🌟 Drug-induced cardiotoxicity is a significant challenge in new drug development. Due to their physiological relevance and reproducibility, cardiac organoids derived from iPSCs are now a game-changer for high-throughput drug safety screening. At ACROBiosystems, we've developed cardiac organoids that accurately predict drug-induced cardiotoxicity. But we don't stop there! Our ongoing research also covers other organoid models, including brain, liver, and intestines, to offer comprehensive support for future clinical trials. Join us at the forefront of innovation in drug development! 💊✨ 🔗https://lnkd.in/gzPuS_xg #Biotech #DrugDevelopment #Organoids #iPSCs #AllianzBioinnovation #Research #India #ACROBiosystems

TSH Biopharm (TW:8432) announced on the 22nd that it signed a five-year cooperation memorandum (MOU) with the National Yang Ming Chiao Tung University, Medical School. This cooperation focuses on the two key points of "talent cultivation" and "precision drug development". Through early verification of new functions of specific targets and AI screening drugs for vascular disease, organ protection and anti-aging , it will improve the success rate of new drug development, shorten the time to market and reduce costs. #AI new target screening #National Yang Ming Chiao Tung University #TSH Biopharm #Vascular disease, organ protection and anti-aging https://lnkd.in/gtxrAVD6

Introducing HYBRID-ON: A Breakthrough in Oligonucleotide Detection! At ADViRNA, we’re proud to unveil HYBRID-ON, our innovative ELISA-based assay designed to tackle the challenges of detecting therapeutic oligonucleotides. Our HYBRID-ON assay changes the game with: ✅ Sequence-agnostic detection for various oligonucleotides. ✅ High sensitivity (1-1000 fmol), perfect for small sample sizes. ✅ Adaptability to multiple sample types like cultured cells, plasma, and tissues. ✅ Optimized for chemically modified oligonucleotides. Whether you’re investigating siRNA, ASOs, or other therapeutic oligonucleotides, HYBRID-ON simplifies and enhances the detection process. Want to learn more about how HYBRID-ON can improve your research? Contact us today! https://lnkd.in/erNW4Aer #RNAi #OligonucleotideResearch #siRNA #ELISA #ADViRNA #Biodistribution #HybridOn #Therapeutics #Innovation

🔬 Dive Into #AntibodyDrugConjugate #Pharmacokinetics With Our Advanced Immunoassay (#ELISA) And Mass Spectrometry (#LCMS) Capabilities 🔍 ⚖️ Achieve Efficacy & Safety: Balance The Scales With Comprehensive #PK Analysis And #DrugDrugInteraction Profiling, Securing Your Transition From Research To #ClinicalTrials  📊 Review #Biodistribution & Catabolism: Direct The Progression From #InVitro #Potency Assays To #InVivo Tissue Distribution, Shaping Therapeutic Strategies For Superior Patient Outcomes  🛠️ Assess Linker Stability & Deconjugation: Reveal The Resilience Of ADC #Linkers Across Varied #Biological Systems, Customizing Precise Human PK Dosing Regimens 💡Partner With NorthEast Biolab For One-Stop #Bioanalytical Expertise In ADC PK And Beyond. Let’s Embark On Your #DrugDevelopment Voyage As We Unravel The Complexities Of ADCs To Forge Pathbreaking Treatments! https://lnkd.in/dw2ra3KM

Novartis Reports Updated Results from the P-IIIb (SMART) Trial of Zolgensma for Treating Spinal Muscular Atrophy (SMA) #novartis #zolgensma #spinalmuscularatrophy #clinicaltrial #piii #smart #sma #treatment #symptomaticsma #biallelicmutations #smn1gene #smn2gene #transaminases #thrombocytopenia #rulm #hfmse

Tryptamine Therapeutics (ASX:TYP) (Tryp Therapeutics), playing in the emerging space of #PsychedelicMedicine, has wrapped up a Phase 1b trial of an innovative psilocin-based IV-infusion which could have neuroplastic benefits. Proactive’s Tylah Tully provides #JustTheFacts on the company’s latest news, which includes sign off by the Safety Review Council on the trial and an update on the study’s findings. All trial participants achieved rapid onset of the psychedelic state, compared to one to two hours observed in oral #psilocybin trials. Treatments which improve neuroplasticity are known to cause adaptive structural and functional changes within the brain, with a vast range of implications for medical science. “From a research perspective, Tryp has now established the strong foundations essential to advance our world-first trials for IV-infused psilocin to the highest standards of safety, quality and integrity," CEO Jason Carroll said. Read more on our website https://ow.ly/X2ex50UcnSy #ProactiveInvestors #ASX #TYP #Neuroplasticity #Psilocin #PsychedelicTherapy

Vesper Bio is pleased to announce the successful completion of the Phase I study for our lead candidate #VES001, a potentially disease-modifying treatment for #frontotemporaldementia. VES001 is a first-in-class oral, brain penetrant, small molecule sortilin inhibitor designed as a potentially disease-modifying treatment for #FTD. With its unique mode of action and convenient oral daily dosing, VES001 is an ideal, patient friendly treatment option. The Phase I study was a two part trial in 78 healthy volunteers investigating safety, tolerability, pharmacokinetics and pharmacodynamic target engagement across single and multiple ascending dose levels. All endpoints were successfully met, with high safety and tolerability observed across the full range of doses tested. Increased progranulin levels were observed across a range of separate dose levels, showing strong target engagement levels alongside the excellent pharmacokinetic profile of VES001. These data generated in our Phase I trial demonstrate the potential of sortilin inhibition as a therapeutic approach to the treatment of FTD, and brings us one step closer to transforming patient outcomes in such a devastating disease. You can read the full press release via the link in the comments below. #sortilin #biotech #clinicaltrial